Skip to content

Pipeline

During the third quarter of 2022, Aqilion took the major step from preclinical development to clinical Phase 1.

As of September 30, 2022, the company has four development programs, in various stages of development, in its pipeline.

All programs focus on developing novel innovative treatments for chronic inflammatory diseases for which few or no treatments are available and where there is currently a clear patient need.

Program
Target
Drug Candidate
Target Discovery
Development of Drug Candidate
IND enabling preclinical development
Phase 1
Phase 2
Regulus
JAK1
AQ280
Girtab
AhR
AQ312
Alnitak
TAK1
Not disclosed
Alnitak
TAK1 CNS penetrant
Not disclosed
Polaris
Not disclosed
Not disclosed